🏅 FDA Orphan Designation
Triostat
Liothyronine sodium injection
Manufacturer: SmithKline Beecham Pharmaceuticals
FDA-Approved Indications (2)
Hypo- and hypermelanotic cutaneous macules-retarded growth-intellectual disability syndromeOrphan Designation
Treatment of myxedema coma/precoma.
Indications & Usage
Treatment of myxedema coma/precoma.
💙 Support Programs
View all →Triostat
SmithKline Beecham Pharmaceuticals
Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.
Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.